Get the Stockscreener App
3.25
4.80%
0.1488
After Hours:
3.25
Evaxion A S Adr stock is traded at $3.25, with a volume of 74,198.
It is up +4.80% in the last 24 hours and up +24.52% over the past month.
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
See More
Previous Close:
$3.1012
Open:
$3.15
24h Volume:
74,198
Relative Volume:
0.64
Market Cap:
$20.53M
Revenue:
-
Net Income/Loss:
$-11.46M
P/E Ratio:
-0.2321
EPS:
-14
Net Cash Flow:
$-24.56M
1W Performance:
+12.85%
1M Performance:
+24.52%
6M Performance:
+28.46%
1Y Performance:
-78.69%
1-Day Range:
$3.10
$3.29
1-Week Range:
$2.90
$3.40
52-Week Range:
$1.20
$17.75
Evaxion A S Adr Stock (EVAX) Company Profile
Compare EVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion A S Adr
|
3.25 | 20.34M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Evaxion A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion A S Adr Stock (EVAX) Latest News
XTX Topco Ltd Makes New Investment in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) - Defense World
Evaxion Biotech Reports Q2 2025 Financial Results - TipRanks
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 - GlobeNewswire Inc.
Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 148.8% - Defense World
Evaxion Boosts Equity through Debt Conversion, Improves Financial Flexibility - AInvest
Healthcare Stocks to Watch: Evaxion Biotech, CVRx, and Rockwell Medical Receive Bullish Sentiments - AInvest
Biotech Contrarians: Seizing Value in Europe's ADRs Amid Sectoral Slump - AInvest
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
EVAX: Grant For Polio Vaccine Announced - Research Tree
Evaxion Biotech’s Earnings Call Highlights Progress and Challenges - MSN
Evaxion Biotech Reports Q1 2025 Progress and Financials - TipRanks
European ADRs Rise On S&P Europe Select Index - Finimize
European Equities See Growth In US Trade - Finimize
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Evaxion’s EVX-01 vaccine shows promising immune response in trial - Investing.com
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
European Stocks Slip In US Trading With Mixed Performances - Finimize
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech A/SADR to Host Earnings Call - ACCESS Newswire
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
Evaxion secures Nasdaq listing with equity boost - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline - Investing.com
Evaxion Biotech Completes 1:5 Reverse ADS Split: What Investors Need to Know - Stock Titan
Evaxion Biotech stock hits 52-week low at $0.81 amid market challenges - Investing.com
Evaxion Biotech A/S Announces Change in American Depositary Shares Ratio to Enhance Liquidity - Nasdaq
Evaxion Biotech stock hits 52-week low at $0.84 amid market challenges - Investing.com
Evaxion Biotech stock hits 52-week low at $0.92 - Investing.com
Evaxion achieves preclinical success with AI cancer vaccine - Investing.com
Earnings call: Evaxion Biotech reports Q2 results, optimistic on EVX-01 - Investing.com
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now - Nasdaq
Evaxion A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):